Babichev et al. examined the role of phosphatidylinositol 3-kinase/AKT/mammalian target of the rapamycin (PI3K/AKT/mTOR) pathway inhibitors in conjunction with doxorubicin and found a decrease in cell viability with combination therapies in a soft tissue sarcoma cell line and in the SK-LMS-1 cell line. This evidence concerns the gene AKT1 and soft tissue sarcoma.